Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | PDE8B | O95263 | 1/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | IL1B | P01584 | 1/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1401178 | 0.84 | HSD17B10 (0.49) | HSD17B10ATMSMN1; SMN2ALDH1A1PDE8B | |
| SCHEMBL20522096 | 0.84 | HSD17B10 (0.49) | HSD17B10ATMSMN1; SMN2ALDH1A1PDE8B | |
| SCHEMBL30416618 | 0.81 | KLK7 (0.48) | OPRD1MEN1KMT2A | |
| SCHEMBL1598307 | 0.80 | CYP2D6 (0.44) | HSD17B10ATMSMN1; SMN2ALDH1A1PDE8B | |
| SCHEMBL1598305 | 0.80 | CYP2D6 (0.44) | HSD17B10ATMSMN1; SMN2ALDH1A1PDE8B | |
| SCHEMBL20893390 | 0.79 | HSD17B10 (0.48) | HSD17B10ATMSMN1; SMN2ALDH1A1PDE8B | |
| SCHEMBL3898258 | 0.79 | HSD17B10 (0.48) | HSD17B10ATMSMN1; SMN2ALDH1A1PDE8B | |
| SCHEMBL25193443 | 0.78 | HSD17B10 (0.38) | HSD17B10SMN1; SMN2ALDH1A1 | |
| SCHEMBL16528528 | 0.78 | HSD17B10 (0.38) | HSD17B10SMN1; SMN2ALDH1A1 | |
| SCHEMBL31296240 | 0.78 | HSD17B10 (0.38) | HSD17B10SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250127801-A1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2025-04-24 | — | — | US | disclosed |
| WO-2025080850-A1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2025-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250127801-A1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND USES THEREOF | SDHA, SDHB, DPYD | HSD17B10 812/4885ATM 3499/4885SMN1; SMN2 2987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.